Effect of Therapeutic Immunization With Recombinant gp160 HIV-1 Vaccine on HIV-1 Proviral DNA and Plasma RNA
- 1 August 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 15 (4) , 269-274
- https://doi.org/10.1097/00042560-199708010-00004
Abstract
Therapeutic vaccination has been proposed as a strategy to augment immune mechanisms to control viral replication and slow clinical progression of HIV infection to disease. Following recombinant gp160 (r-gp160) immunization in three clinical trials, plasma HIV-1 RNA and cellular proviral DNA were assessed by quantitative polymerase chain reaction (PCR) in 76 HIV-seropositive subjects with CD4+ T cell counts > or = 300/mm3. Immunization increased HIV-specific cellular immune responses (e.g., cytotoxic T lymphocyte [CTL] activities, lymphocyte proliferative responses); however, there were no significant effects of immunization or cellular immune responses on measures of plasma RNA or cellular DNA viral load.Keywords
This publication has 19 references indexed in Scilit:
- A Randomized, Placebo-Controlled Study of the Immunogenicity of Human Immunodeficiency Virus (HIV) rgp160 Vaccine in HIV-Infected Subjects with >=400/mm3 CD4 T Lymphocytes (AIDS Clinical Trials Group Protocol 137)The Journal of Infectious Diseases, 1996
- Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of InfectionScience, 1996
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival.Proceedings of the National Academy of Sciences, 1995
- Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1995
- Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.Proceedings of the National Academy of Sciences, 1992
- A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Recombinant HIV Structural Proteins Detect Specific Cellular Immunity In Vitro in Infected IndividualsAIDS Research and Human Retroviruses, 1988
- Prospects for the control of AIDS by immunizing seropositive individualsNature, 1987
- Immunization against AIDS in humansNature, 1987